Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 6/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.41 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.41 |
| ▸ | SLC28A3 | Q9HAS3 | 2/20 | 0.41 |
| ▸ | SELE | P16581 | 1/20 | 0.41 |
| ▸ | IGF2R | P11717 | 1/20 | 0.40 |
| ▸ | FGF1 | P05230 | 1/20 | 0.40 |
| ▸ | FGF2 | P09038 | 1/20 | 0.40 |
| ▸ | VEGFA | P15692 | 1/20 | 0.40 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19499655 | 0.96 | LGALS8 (0.51) | LGALS8L3MBTL1MEN1KMT2APTPN1 | |
| SCHEMBL29378663 | 0.96 | LGALS8 (0.51) | LGALS8L3MBTL1MEN1KMT2APTPN1 | |
| SCHEMBL19499656 | 0.93 | LGALS8 (0.47) | LGALS8L3MBTL1PTPN1LGALS3IGF2R | |
| SCHEMBL29375702 | 0.93 | LGALS8 (0.47) | LGALS8L3MBTL1PTPN1LGALS3IGF2R | |
| SCHEMBL24495271 | 0.92 | LGALS8 (0.48) | LGALS8L3MBTL1MEN1KMT2APTPN1 | |
| SCHEMBL29379207 | 0.88 | LGALS8 (0.45) | LGALS8MEN1KMT2ALGALS3LGALS4 | |
| SCHEMBL24495058 | 0.88 | LGALS8 (0.45) | LGALS8PTPN1LGALS3LGALS4SELE | |
| SCHEMBL19499653 | 0.87 | AMY1A (0.39) | LGALS8L3MBTL1MEN1KMT2ALGALS3 | |
| SCHEMBL29376308 | 0.87 | AMY1A (0.39) | LGALS8L3MBTL1MEN1KMT2ALGALS3 | |
| SCHEMBL24494995 | 0.87 | LGALS8 (0.44) | LGALS8L3MBTL1PTPN1LGALS3SELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177507-A1 | NOVEL COMPOUND AND USE OF SAME | NAGASE & CO., LTD. (JP) | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177507-A1 | NOVEL COMPOUND AND USE OF SAME | TXNRD2, GPX4, GPX1 | LGALS8 3562/4885L3MBTL1 2318/4885MEN1 2937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.